TY - JOUR
T1 - Drug repurposing from an academic perspective
AU - Oprea, Tudor I.
AU - Bauman, Julie E.
AU - Bologa, Cristian G.
AU - Buranda, Tione
AU - Chigaev, Alexandre
AU - Edwards, Bruce S.
AU - Jarvik, Jonathan W.
AU - Gresham, Hattie D.
AU - Haynes, Mark K.
AU - Hjelle, Brian
AU - Hromas, Robert
AU - Hudson, Laurie
AU - MacKenzie, Debra A.
AU - Muller, Carolyn Y.
AU - Reed, John C.
AU - Simons, Peter C.
AU - Smagley, Yelena
AU - Strouse, Juan
AU - Surviladze, Zurab
AU - Thompson, Todd
AU - Ursu, Oleg
AU - Waller, Anna
AU - Wandinger-Ness, Angela
AU - Winter, Stuart S.
AU - Wu, Yang
AU - Young, Susan M.
AU - Larson, Richard S.
AU - Willman, Cheryl
AU - Sklar, Larry A.
N1 - Funding Information:
This work was supported, in part, by NIH grants 1R21GM095952-01 (TIO), 5U54MH084690-03 (TIO, LAS, CGB), R03MH081231 (AWN), P01CA55164 (JCR), P01CA81543 (JCR), and R21NS066429 (TB); by an institutional grant from the American Cancer Society ( UNM ACS IRG , 10/1/10–9/30/11; JEB); by Department of Defense grant OC 073186 and by UNM Cancer Center FIG 0990Q8, 0990MD (AWN and LGH).
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Academia and small business research units are poised to play an increasing role in drug discovery, with drug repurposing as one of the major areas of activity. Here wesummarize project status for several drugs or classes of drugs: raltegravir, cyclobenzaprine, benzbromarone, mometasone furoate, astemizole, R-naproxen, ketorolac, tolfenamic acid, phenothiazines, methylergonovine maleate and beta-adrenergic receptor drugs, respectively. On the basis of this multi-year, multi-project experience we discuss strengths and weaknesses of academic-based drug repurposing research. Translational, target and disease foci are strategic advantages fostered by close proximity and frequent interactions between basic and clinical scientists, which often result in discovering new modes of action for approved drugs. By contrast, lack of integration with pharmaceutical sciences and toxicology, lack of appropriate intellectual coverage and issues related to dosing and safety may lead to significant drawbacks. The development of a more streamlined regulatory process worldwide, and the development of precompetitive knowledge transfer systems such as a global healthcare database focused on regulatory and scientific information for drugs worldwide, are among the ideas proposed to improve the process of academic drug discovery and repurposing, and to overcomethe 'valley of death' by bridging basic to clinical sciences.
AB - Academia and small business research units are poised to play an increasing role in drug discovery, with drug repurposing as one of the major areas of activity. Here wesummarize project status for several drugs or classes of drugs: raltegravir, cyclobenzaprine, benzbromarone, mometasone furoate, astemizole, R-naproxen, ketorolac, tolfenamic acid, phenothiazines, methylergonovine maleate and beta-adrenergic receptor drugs, respectively. On the basis of this multi-year, multi-project experience we discuss strengths and weaknesses of academic-based drug repurposing research. Translational, target and disease foci are strategic advantages fostered by close proximity and frequent interactions between basic and clinical scientists, which often result in discovering new modes of action for approved drugs. By contrast, lack of integration with pharmaceutical sciences and toxicology, lack of appropriate intellectual coverage and issues related to dosing and safety may lead to significant drawbacks. The development of a more streamlined regulatory process worldwide, and the development of precompetitive knowledge transfer systems such as a global healthcare database focused on regulatory and scientific information for drugs worldwide, are among the ideas proposed to improve the process of academic drug discovery and repurposing, and to overcomethe 'valley of death' by bridging basic to clinical sciences.
UR - http://www.scopus.com/inward/record.url?scp=84862233340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862233340&partnerID=8YFLogxK
U2 - 10.1016/j.ddstr.2011.10.002
DO - 10.1016/j.ddstr.2011.10.002
M3 - Review article
AN - SCOPUS:84862233340
SN - 1740-6773
VL - 8
SP - 61
EP - 69
JO - Drug Discovery Today: Therapeutic Strategies
JF - Drug Discovery Today: Therapeutic Strategies
IS - 3-4
ER -